



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Yechiel SHAI et al

Art Unit: 1653

Application No.: 09/367,714

Conf. No. 4669

Examiner: D. Lukton

Filed: January 14, 2000

Washington, D.C.

For: ANTIPATHOGENIC SYNTHETIC PEPTIDES AND COMPOSITIONS COMPRISING THEM

Atty.'s Docket: SHAI=2

Date: March 19, 2002

RECEIVED

MAR 22 2002

TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [X] Amendment [] _____
in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 27	MINUS	** 30	0
INDEP.	* 1	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	
\$	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	
\$	

OR

OR

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First - \$ 55.00
[] Second - \$ 200.00
[] Third - \$ 460.00
[] Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

[] First - \$ 110.00
[] Second - \$ 400.00
[] Third - \$ 920.00
[] Fourth - \$ 1440.00

Month After Time Period Set

[] Less fees (\$) already paid for ___ month(s) extension of time on _____.

[] Please charge my Deposit Account No. 02-4035 in the amount of \$ _____.


[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____.

[] A check in the amount of \$ _____ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 
Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

RECEIVED

MAR 21 2002

TC 1700



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAR 21 2002
TECH CENTER 1600/2400
1/13/02

Atty. Docket: SHAI=2

In re Application of:)	Conf. No.: 4669
Yechiel SHAI et al)	Art Unit: 1653
Appln. No.: 09/367,714)	Examiner: D. Lukton
Filed: January 14, 2000)	Washington, D.C.
For: ANTIPATHOGENIC SYNTHETIC)	March 19, 2002
PEPTIDES AND COMPOSITIONS)	
COMPRISING THEM)	

AMENDMENT

RECEIVED
MAR 21 2002
TC 1700

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of February 15,
2002, please amend as follows:

IN THE CLAIMS

Delete claims 15-17 and 36 without prejudice towards
the continuation of prosecution thereof in divisional
applications.

Please amend claims 1, 2, 6, 7, 9, 11-14, 20, 21, 34
and 35 as follows:

1 (Thrice-Amended). A non-hemolytic cytolytic
peptide having a selective cytolytic activity manifested in
that it has a cytolytic activity on pathogenic cells, said

E1

F1